We further explored the combination of MSLN-TTC and ATRi in the OVCAR-8 ovarian cancer xenograft model, which had previously demonstrated in vitro synergy from the ATRi combination (Supplemental Fig. 6). Here, MSLN is linked to ovarian carcinoma.